Pharmaceutical Compoundingand Dispensing, Second
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Treatment Effect of Bushen Huayu Extract on Postmenopausal Osteoporosis in Vivo
EXPERIMENTAL AND THERAPEUTIC MEDICINE 7: 1687-1690, 2014 Treatment effect of Bushen Huayu extract on postmenopausal osteoporosis in vivo LU OUYANG1,2, QIUFANG ZHANG1,2,3, XUZHI RUAN3, YIBIN FENG4 and XUANBIN WANG1,2 1Laboratory of Chinese Herbal Pharmacology, Renmin Hospital, Hubei University of Medicine, Shiyan, Hubei 442000; 2School of Pharmacy; 3Basic School of Medicine, Hubei University of Medicine, Shiyan, Hubei 442000; 4School of Chinese Medicine, LKS Faculty, The University of Hong Kong, Hong Kong, SAR, P.R. China Received December 2, 2013; Accepted March 25, 2014 DOI: 10.3892/etm.2014.1661 Abstract. Bushen Huayu extract (BSHY), a traditional Chinese model group (14.75±2.38; P<0.05), and decrease the number medicine, has been demonstrated to treat postmenopausal of osteoclasts in the BSHY-L, BSHY-M and BSHY-H groups osteoporosis, however, the underlying mechanism remains (4.00±1.85, 4.25±1.39 and 5.75±1.49, respectively) compared to be fully elucidated. The aim of the present study was to with 9.50±1.60 observed in the model group (P<0.05). These investigate the therapeutic effect of BSHY and the mecha- results suggest that BSHY is a potential therapeutic drug for nisms underlying this effect in an in vivo postmenopausal the treatment of osteoporosis in vivo. Furthermore, these results osteoporosis animal model. A total of 1 g BSHY containing suggest that the mechanism by which BSHY decreases the 7.12 µg icariin was prepared. Low-dose BSHY (BSHY-L; serum levels of IL-6 may be by regulating E2. 11.1 g/kg), medium-dose BSHY (BSHY-M; 22.2 g/kg) and high-dose BSHY (BSHY-H; 44.4 g/kg) was administered to Introduction oophorectomized rats using intragastric infusion. -
Core Topics in Mechanical Ventilation Edited by Iain Mackenzie Index More Information
Cambridge University Press 978-0-521-86781-8 - Core Topics in Mechanical Ventilation Edited by Iain Mackenzie Index More information Index Abdominal distension in lung elastance oxygen toxicity 270 incidence data 240 345, 346 patient assessment 118, 115–119, 120 laryngeal injuries 248, 247–248 Abdominal paradox 27 recruitment manoeuvres 118–119, left ventricular performance 273 N-Acetylcysteine 79–80, 81, 357, 358 131, 219 lorazepam 165 Acinetobacter baumanii, SDD for 260 trials (See ARDS net trials) lung injury, ventilator-associated (See Acute hypoxaemic respiratory failure ventilation management Lung injury, defined 115 HFOV 127–131, 305–306 ventilator-associated) Acute lung injury (ALI) IRV 125–126 maxillary sinusitis/middle ear blast injuries 212 liquid 228 effusions 246–247 hypoxaemia, PEEP management of modes 215–216 midazolam 165 124–125 overview 214 nasopharyngeal airways 243–245, infants/children 300–301 principles 214–215, 216 246–247 liquid ventilation 228 Acute respiratory failure (ARF) nasotracheal intubation 315 patient assessment 118, 115–119, clinical presentation 29 neurological function 277, 276–277, 120, 197 mechanisms of 24 278, 280 recruitment manoeuvres 131, 219 NIV 43, 49–50 (See also Non-invasive NMBAs 171, 176–177, 276–280 ventilation management ventilation (NIV)) NSAIDs 181 HFV 149–150 overview 24, 22–24, 25, 142 opioid agonists 180 IRV 125–126 Adaptive support ventilation® 113, 361 opioids 276–280 modes 215–216 Adrenaline 81 overview 21, 239, 241 overview 214 Adrenergic receptor antagonists 349, oxygen toxicity -
Camphor Revisited: Focus on Toxicity
Camphor Revisited: Focus on Toxicity Committee on Drugs This commentary updates a previous AAP state- TABLE. List of Camphor-Containing Products ment developed by the Committee on Drugs con- Product % of Camphor cerning camphor.1 The original commentary re- Absorbine Arthritic Pain Lotion 10 flected the level of concern among pediatric Act-On Rub Lotion 1.5 practitioners and poison centers about the toxicity of Anabaim Lotion 3 camphor. Since the original statement, the Food and Aveeno Anti-Itch Conc. Lotion 0.3 t Drug Administration (FDA) has recognized camphor Avalgesic Banaig Muscle Pain Reliever 2 as a safe and effective topical antitussive, analgesic, Bangesic t anesthetic, and antipruritic agent.2 Following the ap- Ben Gay Children’s Vaporizing Rub 5 proval process in 1983, the FDA required that the Betuline Lotion t concentration of camphor in products not exceed Campho-phemque First Aid Gel 10.8 Campho-phenique Uquid 10.85 11%.2 Fligher concentrations were not more effective Campho-phemque Powder 4.375 and could cause more serious adverse reactions if Counterpain Rub t accidentally ingested. Most reported camphor-re- Deep Down Rub 0.5 lated fatalities involved agents containing a concen- Dencorub Cream Dermal Rub t tration greater than 11%. Dermolin Liniment t Ingestion of potentially toxic substances by chil- Emul-O-Balm 1.1 dren is related to the availabffity of a product in their Heet Lotion 3 3.6 environment. Camphor remains widely available Heat Spray Minit-Rub 3.5 (Table). The toxicity of camphor when inappropri- Mollifene Ear Drops t ately used is well documented.6 Ingestion is the Musterole Regular 4 most common route of potentially toxic exposure, Panalgesic 3 with rapid onset of toxic effects. -
IIIHIIIUSOO5304377A Unitedo States Patent 19 (11) Patent Number: 5,304,377 Yamada Et Al
IIIHIIIUSOO5304377A UnitedO States Patent 19 (11) Patent Number: 5,304,377 Yamada et al. (45) Date of Patent: Apr. 19, 1994 54 PROLONGED RELEASE PREPARATION 4,954,298 9/1990 Yamamoto et al. ................. 264/4.6 AND POLYMERS THEREOF 4,962,091 10/1990 Eppstein et al. ........................ 514/2 75) Inventors: Minoru Yamada; Seiko Ishiguro, both 5,061,492 10/1991 Okada et al. ........................ 424/423 Otokuni, all of Japan 0052510 11/1981 European Pat. Off. 73) Assignee: Sherical4. industries, Ltd., O256726O190833 7/19871/1986 European Pat. Off. a, Japan 0263490 10/1987 European Pat. Off. (21) Appl. No.: 986,299 0281482 3/1988 European Pat. Off. 035.0246 7/1989 European Pat. Off. 22 Filed: Dec. 7, 1992 2-212436 8/1990 Japan. Related U.S. Application Data OTHER PUBLICATIONS 63) continuation of ser. No. 777,170, oct. 16, 1991, aban- Chemical Abstracts, vol. 114/No. 6 (Feb. 11, 1991); doned. Columbus, Ohio; Abstract No. 49615R. 30 Foreign Application Priority Data Primary Ent, S. Sir Mueller & Oct. 16, 1990 (JP) Japan .................................. 2-278037 story Agent, or Firm-Wegner, Cantor, Mueller Aug. 28, 1991 JP Japan .................................. 3.217045 51 Int, Cl. ......................... A61K 9/22; A61K 9/52; ' ABSTRACT A61K 31/74 A polymer for a prolonged release preparation which 52 U.S. Cl. ................................. 424/426; 424/78.08; comprises 424/78.37; 424/434; 424/457; 424/468; (A) a polylactic acid and 424/486; 424/497; 525/450, 514/2 (B) a copolymer of glycolic acid and a hydroxycar 58) Field of Search .................. 424/426, 78.08, 78.37, boxylic acid of general formula 424/434, 457, 468, 486, 497; 525/450; 514/2 (56) References Cited R U.S. -
(12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 De Juan Et Al
US 200601 10428A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 de Juan et al. (43) Pub. Date: May 25, 2006 (54) METHODS AND DEVICES FOR THE Publication Classification TREATMENT OF OCULAR CONDITIONS (51) Int. Cl. (76) Inventors: Eugene de Juan, LaCanada, CA (US); A6F 2/00 (2006.01) Signe E. Varner, Los Angeles, CA (52) U.S. Cl. .............................................................. 424/427 (US); Laurie R. Lawin, New Brighton, MN (US) (57) ABSTRACT Correspondence Address: Featured is a method for instilling one or more bioactive SCOTT PRIBNOW agents into ocular tissue within an eye of a patient for the Kagan Binder, PLLC treatment of an ocular condition, the method comprising Suite 200 concurrently using at least two of the following bioactive 221 Main Street North agent delivery methods (A)-(C): Stillwater, MN 55082 (US) (A) implanting a Sustained release delivery device com (21) Appl. No.: 11/175,850 prising one or more bioactive agents in a posterior region of the eye so that it delivers the one or more (22) Filed: Jul. 5, 2005 bioactive agents into the vitreous humor of the eye; (B) instilling (e.g., injecting or implanting) one or more Related U.S. Application Data bioactive agents Subretinally; and (60) Provisional application No. 60/585,236, filed on Jul. (C) instilling (e.g., injecting or delivering by ocular ion 2, 2004. Provisional application No. 60/669,701, filed tophoresis) one or more bioactive agents into the Vit on Apr. 8, 2005. reous humor of the eye. Patent Application Publication May 25, 2006 Sheet 1 of 22 US 2006/0110428A1 R 2 2 C.6 Fig. -
Absorbine Veterinary Liniment for Horses
Doc# 03.287 Ver. 11 SAFETY DATA SHEET ABSORBINE® VETERINARY LINIMENT SECTION 1 - PRODUCT AND COMPANY IDENTIFICATION 1.1 Trade Name (as labeled): Absorbine® Veterinary Liniment Synonyms: N/A CAS No: Mixture 1.2 Product Use: Soothes sore muscles and stiff joints 1.3 Company Name: W.F. Young Company Address: 302 Benton Dr Company Address Cont: East Longmeadow, MA 01028 Business Phone: ( 413) 526-9999 Website: www.wfyoung.com 1.4 Emergency Telephone Number: (413) 526-9999 Date of Current Revision: January 17, 2017 Date of Last Revision: August 7, 2015 SECTION 2 - HAZARD IDENTIFICATION EMERGENCY OVERVIEW: This product is a green thin liquid with an acetone odor. Health Hazards: May cause skin, eye, and respiratory system irritation. Flammabilit Hazards: This product is a flammable liquid with a flash point over 20°F (-6. 7°C). Reactivit Hazards: None. Environmental Hazards: The environmental effectsof this product have not been investigated, however release may cause long term adverse environmental effects. US DOT Symbols: EU and GHS Symbols: Signal Word: Danger! 2.1 CLASSIFICATION OF SUBSTANCE OR MIXTURE IN ACCORDANCE WITH 29 CFR 1200 (OSHA HCSl AND THE EUROPEAN UNION DIRECTIVES: This product does meet the definition of a hazardous substance or preparation as defined by 29 CFR 1910. 1200 or the European Union Council Directives 67 /548/EEC, 1999/45/EC, 1272/2008/EC and subsequent Directives. EU HAZARD CLASSIFICATIONOF INGREDIENTS PER DIRECTIVE 1272/2008/EC: IndexNumber: EC# 201-939-0 This substance is not classified in the AnnexVI of Directive 67/548/EEC EC# 200-662-2 This substance is classified in the AnnexVI of Directive 67/548/EEC Index# 606-001-00-8 Substances not listed either individually or in group entries must be self classified. -
(12) United States Patent (10) Patent No.: US 7.803,838 B2 Davis Et Al
USOO7803838B2 (12) United States Patent (10) Patent No.: US 7.803,838 B2 Davis et al. (45) Date of Patent: Sep. 28, 2010 (54) COMPOSITIONS COMPRISING NEBIVOLOL 2002fO169134 A1 11/2002 Davis 2002/0177586 A1 11/2002 Egan et al. (75) Inventors: Eric Davis, Morgantown, WV (US); 2002/0183305 A1 12/2002 Davis et al. John O'Donnell, Morgantown, WV 2002/0183317 A1 12/2002 Wagle et al. (US); Peter Bottini, Morgantown, WV 2002/0183365 A1 12/2002 Wagle et al. (US) 2002/0192203 A1 12, 2002 Cho 2003, OOO4194 A1 1, 2003 Gall (73) Assignee: Forest Laboratories Holdings Limited 2003, OO13699 A1 1/2003 Davis et al. (BM) 2003/0027820 A1 2, 2003 Gall (*) Notice: Subject to any disclaimer, the term of this 2003.0053981 A1 3/2003 Davis et al. patent is extended or adjusted under 35 2003, OO60489 A1 3/2003 Buckingham U.S.C. 154(b) by 455 days. 2003, OO69221 A1 4/2003 Kosoglou et al. 2003/0078190 A1* 4/2003 Weinberg ...................... 514f1 (21) Appl. No.: 11/141,235 2003/0078517 A1 4/2003 Kensey 2003/01 19428 A1 6/2003 Davis et al. (22) Filed: May 31, 2005 2003/01 19757 A1 6/2003 Davis 2003/01 19796 A1 6/2003 Strony (65) Prior Publication Data 2003.01.19808 A1 6/2003 LeBeaut et al. US 2005/027281.0 A1 Dec. 8, 2005 2003.01.19809 A1 6/2003 Davis 2003,0162824 A1 8, 2003 Krul Related U.S. Application Data 2003/0175344 A1 9, 2003 Waldet al. (60) Provisional application No. 60/577,423, filed on Jun. -
)&F1y3x PHARMACEUTICAL APPENDIX to THE
)&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE -
Genl:VE 1970 © World Health Organization 1970
Nathan B. Eddy, Hans Friebel, Klaus-Jiirgen Hahn & Hans Halbach WORLD HEALTH ORGANIZATION ORGANISATION .MONDIALE DE LA SANT~ GENl:VE 1970 © World Health Organization 1970 Publications of the World Health Organization enjoy copyright protection in accordance with the provisions of Protocol 2 of the Universal Copyright Convention. Nevertheless governmental agencies or learned and professional societies may reproduce data or excerpts or illustrations from them without requesting an authorization from the World Health Organization. For rights of reproduction or translation of WHO publications in toto, application should be made to the Division of Editorial and Reference Services, World Health Organization, Geneva, Switzerland. The World Health Organization welcomes such applications. Authors alone are responsible for views expressed in signed articles. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the Director-General of the World Health Organization concerning the legal status of any country or territory or of its authorities, or concerning the delimitation of its frontiers. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters. © Organisation mondiale de la Sante 1970 Les publications de l'Organisation mondiale de la Sante beneficient de la protection prevue par les dispositions du Protocole n° 2 de la Convention universelle pour la Protection du Droit d'Auteur. Les institutions gouvernementales et les societes savantes ou professionnelles peuvent, toutefois, reproduire des donnees, des extraits ou des illustrations provenant de ces publications, sans en demander l'autorisation a l'Organisation mondiale de la Sante. Pour toute reproduction ou traduction integrate, une autorisation doit etre demandee a la Division des Services d'Edition et de Documentation, Organisation mondiale de la Sante, Geneve, Suisse. -
NINDS Custom Collection II
ACACETIN ACEBUTOLOL HYDROCHLORIDE ACECLIDINE HYDROCHLORIDE ACEMETACIN ACETAMINOPHEN ACETAMINOSALOL ACETANILIDE ACETARSOL ACETAZOLAMIDE ACETOHYDROXAMIC ACID ACETRIAZOIC ACID ACETYL TYROSINE ETHYL ESTER ACETYLCARNITINE ACETYLCHOLINE ACETYLCYSTEINE ACETYLGLUCOSAMINE ACETYLGLUTAMIC ACID ACETYL-L-LEUCINE ACETYLPHENYLALANINE ACETYLSEROTONIN ACETYLTRYPTOPHAN ACEXAMIC ACID ACIVICIN ACLACINOMYCIN A1 ACONITINE ACRIFLAVINIUM HYDROCHLORIDE ACRISORCIN ACTINONIN ACYCLOVIR ADENOSINE PHOSPHATE ADENOSINE ADRENALINE BITARTRATE AESCULIN AJMALINE AKLAVINE HYDROCHLORIDE ALANYL-dl-LEUCINE ALANYL-dl-PHENYLALANINE ALAPROCLATE ALBENDAZOLE ALBUTEROL ALEXIDINE HYDROCHLORIDE ALLANTOIN ALLOPURINOL ALMOTRIPTAN ALOIN ALPRENOLOL ALTRETAMINE ALVERINE CITRATE AMANTADINE HYDROCHLORIDE AMBROXOL HYDROCHLORIDE AMCINONIDE AMIKACIN SULFATE AMILORIDE HYDROCHLORIDE 3-AMINOBENZAMIDE gamma-AMINOBUTYRIC ACID AMINOCAPROIC ACID N- (2-AMINOETHYL)-4-CHLOROBENZAMIDE (RO-16-6491) AMINOGLUTETHIMIDE AMINOHIPPURIC ACID AMINOHYDROXYBUTYRIC ACID AMINOLEVULINIC ACID HYDROCHLORIDE AMINOPHENAZONE 3-AMINOPROPANESULPHONIC ACID AMINOPYRIDINE 9-AMINO-1,2,3,4-TETRAHYDROACRIDINE HYDROCHLORIDE AMINOTHIAZOLE AMIODARONE HYDROCHLORIDE AMIPRILOSE AMITRIPTYLINE HYDROCHLORIDE AMLODIPINE BESYLATE AMODIAQUINE DIHYDROCHLORIDE AMOXEPINE AMOXICILLIN AMPICILLIN SODIUM AMPROLIUM AMRINONE AMYGDALIN ANABASAMINE HYDROCHLORIDE ANABASINE HYDROCHLORIDE ANCITABINE HYDROCHLORIDE ANDROSTERONE SODIUM SULFATE ANIRACETAM ANISINDIONE ANISODAMINE ANISOMYCIN ANTAZOLINE PHOSPHATE ANTHRALIN ANTIMYCIN A (A1 shown) ANTIPYRINE APHYLLIC -
View of Our Data Collection Tool
University of Alberta Pharmacists’ Beliefs about Bioidentical Hormone Therapy by Tasneem Siyam A thesis submitted to the Faculty of Graduate Studies and Research in partial fulfillment of the requirements for the degree of Master of Science in Pharmacy practice Faculty of Pharmacy and Pharmaceutical Sciences © Tasneem Siyam Spring 2012 Edmonton, Alberta Permission is hereby granted to the University of Alberta Libraries to reproduce single copies of this thesis and to lend or sell such copies for private, scholarly or scientific research purposes only. Where the thesis is converted to, or otherwise made available in digital form, the University of Alberta will advise potential users of the thesis of these terms. The author reserves all other publication and other rights in association with the copyright in the thesis and, except as herein before provided, neither the thesis nor any substantial portion thereof may be printed or otherwise reproduced in any material form whatsoever without the author's prior written permission. ABSTRACT OBJECTIVE: To identify pharmacists’ beliefs about bioidentical hormone therapy (BHT) and determine factors influencing these beliefs. METHODS: This was a cross-sectional survey targeting practicing pharmacists in Alberta. Participants completed a 54-item, online questionnaire, designed to capture their demographics, as well as their beliefs about BHT. Summary statistics and multivariate regression were used for analyses. Qualitative components were analyzed using phenomenological approach. RESULTS: Over half of respondents believed BHT had equal efficacy and risks as non-bioidentical hormones. Beliefs on estriol, natural progesterone, and saliva testing however, were more diverse with many do not know responses (40%). In multivariate analysis, BHT compounding practice was associated with beliefs about BHT. -
OHAUS New Scout Balance Range
Catalogue OHAUS new Scout Balance Range Touchscreen Page 121 Memmert Ovens & Incubators New bollé German Made Page 140 Rush Plus Small Has Arrived Page 77 Schott-DURAN Youtility Bottles A New Age Page 6 SAVINGS Up to 70% off major brands Bacto Laboratories Feb 2018 BactoIssue Laboratories 7.5 Pty Ltd - Phone (02) 9823-9000Proudly - Email [email protected] Supplying - (prices Science excl GST) Since 1966 1 Contents A Centrifuge 145 Flask, Volumetric Glass 17 Alcohol Wipes 55 Centrifuge Tube, Glass 24 Flask, Volumetric Plastic 29 Analytical Balance 117 Centrifuge Tube, Plastic 44 Forceps 88 Aspirator Bottle, Plastic 42 Chemicals 67 Forceps, Artery 92 Autoclave Indicators 59 Clamps, Bosshead 96 Fridge Thermometers 102 Autoclave Tape 59 Clamps, Burettes 97 Funnel, Glass 15 Autoclave Waste Bags 61 Clamps, Retort 96 Funnel, Plastic 30 Clinical Centrifuge 145 G - H B Coats, Laboratory 74 Gloves, Examination 72 Bacticinerator 82 Cold Bricks 69 Gloves, Safety 71 Bags, Waste 61 Colony Counter 81 Gowns 75 Balance, Moisture 119 Conductivity Meter 109 Hand Wash, Alcohol 55 Balances 116 Conical Measure, Plastic 27 Hand Wash, Cleanser 56 Batteries 102 Contaminated Waste Bags 62 Hand Wash, Sanitiser 55 Beaker, Glass 11 Coplin Jar 53 Hockey Stick 50 Beaker, Plastic 27 Corrosive Cabinets 85 Hotplate 124 Bench Roll 58 Cover Slips, Glass 52 Hotplate Stirrer 124 Biju McCartney Bottle 25 Cryo Vial, Plastic 37 Hygrometers 102 Bins, Broken Glass 61 Culture Media 50 I Bins, Chemotherapy 65 Culture Tube, Glass 24 Incubator 138 Bins, Contaminated Waste 61 Cuvettes,